Annovis Bio ANVS 深 滬
等待開盤 10-28 09:30:00 美东时间
1.00
+0.043
+4.49%
華盛通- 最 高1.03
- 今 開0.95
- 成交量 91.33万股
- 最 低 0.95
- 昨 收 0.957
- 總市值 4267.91万
- 52周最高 5.50
- 市盈率 靜 --
- 換手率 2.14%
- 52周最低 0.9295
- 委 比 80.00%
- 總股本 4267.91万
- 歷史最高 132.00
- 量 比 1.75
- 振 幅 8.36%
- 歷史最低 0.9295
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Annovis Bio收跌4.23%，成交额56.42万美元
10月27日，Annovis Bio（ANVS）收跌4.23%，报0.96美元，成交额56.42万美元，市值4084.35万美元。 行情数据 • 开盘价：1美元...
10-27 07:30
Annovis to Attend the CTAD 2026 with Three Presentations
Annovis Bio will present three sessions at the 19th CTAD conference in Boston, showcasing buntanetap's mechanism, AI-driven drug evaluation, and Phase 3 trial updates, reflecting progress toward a 2027 data readout and NDA preparation.
10-22 12:00
Annovis Bio收跌5.39%，成交额65.25万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:33
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
Annovis Bio collaborates with Weave Bio to support the NDA submission for buntanetap, an investigational therapy for Alzheimer’s and Parkinson’s diseases. Using Weave’s AI platform, Annovis aims to prepare most of the NDA documents before the Phase 3 AD trial’s 6-month data readout, streamlining the submission process. The Phase 3 study enrolled 862 patients, exceeding its target, with data expected in March 2027. Annovis and Weave align with FDA...
09-23 12:00
美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
Annovis to Host Corporate Update Webinar on September 2, 2026
Annovis Bio, a Phase 3 biotech company, will host a webinar on September 2, 2026, at 4:00 p.m. EDT, led by CEO Maria Maccecchini. The event will cover recent progress, including full enrollment in their pivotal Phase 3 Alzheimer's disease trial, plans for long-term safety studies, and ongoing Parkinson's disease research. The company aims to share updates with stakeholders and maintain transparency.
08-25 12:00
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 25 percent decrease over losses of $(0.32) per share from the same period last year.
08-14 20:10
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Annovis Bio has achieved full enrollment in its pivotal Phase 3 Alzheimer’s disease (AD) trial with 850 patients, exceeding its original target. The company also reported progress in its Parkinson’s disease (PD) open-label extension study, which has enrolled 266 patients toward a goal of 500. Annovis will host a corporate update webinar on September 2, 2026, to discuss these developments. Additionally, the company provided financial results, incl...
08-14 12:00
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
Roth Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $8
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $8.
07-08 17:08
